Here's why Su­cam­po paid $200M for its PhI­II Nie­mann-Pick drug

In­ves­ti­ga­tors have out­lined the re­sults of a small, sin­gle-arm study of a new drug for Nie­mann-Pick type C dis­ease which in­spired a $200 mil­lion biotech buy­out ear­li­er this year.

The drug is cy­clodex­trin, or at least a unique mix­ture of 2-hy­drox­ypropyl-ß- cy­clodex­trins (HPßCD) that Vtesse had moved in­to a piv­otal study af­ter glean­ing pos­i­tive da­ta from a study with 14 pa­tients. Su­cam­po bagged the biotech and its drug for $200 mil­lion in April, tak­ing over con­trol of the Phase III.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER